FDA hands CRL to Abeon­a's rare skin dis­ease cell ther­a­py

Abeona Ther­a­peu­tics’ shares dropped by al­most 50% pre-mar­ket Tues­day af­ter re­ceiv­ing an FDA com­plete re­sponse let­ter for its cell ther­a­py for epi­der­mol­y­sis bul­losa. The as­set …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER